thirdgeneration recombinant immunoblot assay (riba (Quidel)
Quidel is a verified supplier 
Quidel manufactures this product 
90
Structured Review
Quidel
thirdgeneration recombinant immunoblot assay (riba
Thirdgeneration Recombinant Immunoblot Assay (Riba, supplied by Quidel, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thirdgeneration+recombinant+immunoblot+assay+(riba/recombinant+immunoblot+assay++riba/pm19638157-31-7-16
Average 90 stars, based on 1 article reviews
Thirdgeneration Recombinant Immunoblot Assay (Riba, supplied by Quidel, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thirdgeneration+recombinant+immunoblot+assay+(riba/recombinant+immunoblot+assay++riba/pm19638157-31-7-16
Average 90 stars, based on 1 article reviews
thirdgeneration recombinant immunoblot assay (riba - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Recombinant:Article Title: Hepatitis C virus incident cases open the possibility to study transmission route and source of infection. Article Snippet: rapid clearance of D+ red blood cells, and assessment of the potential risk of a severe hemolytic episode.. While the risk of immunocompetent patients forming anti-D after mismatched transfusion may not be as high as in the obstetrical setting, the rate of alloimmunization in the recent studies cited in our review is still not trivial.. Consideration of anti-D use for D-mismatched transfusions should be made on a case-by-case basis. Western Blot:Article Title: Hepatitis C virus incident cases open the possibility to study transmission route and source of infection. Article Snippet: rapid clearance of D+ red blood cells, and assessment of the potential risk of a severe hemolytic episode.. While the risk of immunocompetent patients forming anti-D after mismatched transfusion may not be as high as in the obstetrical setting, the rate of alloimmunization in the recent studies cited in our review is still not trivial.. Consideration of anti-D use for D-mismatched transfusions should be made on a case-by-case basis. |